Please login to the form below

Not currently logged in
Email:
Password:

injectables

This page shows the latest injectables news and features for those working in and with pharma, biotech and healthcare.

Merck’s backing of NGM Bio yields NASH drug deal

Merck’s backing of NGM Bio yields NASH drug deal

The mid-stage candidate, called NGM313, is an antibody targeting the beta-Klotho/FGFR1c receptor complex that Merck describes as a “once-monthly injectable insulin sensitizer” and could represent a whole

Latest news

More from news
Approximately 3 fully matching, plus 358 partially matching documents found.

Latest Intelligence

  • Key considerations for disease- modifying Parkinson’s disease trials Key considerations for disease- modifying Parkinson’s disease trials

    consequence. Take special measures to ensure adherence to the investigation product for non- injectable therapies.This is mandatory for all long-lasting prophylactic treatments.

  • The sound of silence puts the squeeze on generics and biosimilars The sound of silence puts the squeeze on generics and biosimilars

    The issues that need urgent discussion are sectors with 100% generic penetration, such as hospital injectables and oncology products where there is no growth, yet companies have to contend with rising

  • Deal Watch - May 2017 Deal Watch - May 2017

    is making two acquisitions worth over $5.5bn.  The acquisition of Akorn, a US based company that manufactures “alternate” formulations such as liquids, gels and injectables  and markets a range of ... strengthen Kabi’s already strong position

  • Deal Watch March 2017 Deal Watch March 2017

    Sihuan Pharmaceuticals, a leader in China’s cardio-cerebrovascular area, has acquired the manufacturer Ambest Pharmaceuticals, with its portfolio of injectable products, for $160m. ... 190. Ambest Pharmaceutical. Sihuan Pharmaceutical. Acquisition.

  • Deal Watch November 2016 Deal Watch November 2016

    The company has manufacturing facilities covering APIs and a wide variety of dosage forms ranging from injectables to tablets, creams and gels. ... Eagle's current focus is on the development of novel, optimised formulations of FDA-approved injectable

More from intelligence
Approximately 0 fully matching, plus 28 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Weber Shandwick

At Weber Shandwick, engagement has always been the cornerstone of health communications.We make health matter. Health is a basic human...

Latest intelligence

China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...

Infographics